@inproceedings{oai:repo.qst.go.jp:00054393,
 author = {Kamada, Tadashi and Imai, Reiko and Serizawa, Itsuko and 鎌田 正 and 今井 礼子 and 芹澤 慈子},
 book = {International Journal of Clinical Oncology},
 issue = {15S},
 month = {May},
 note = {Carbon ion radiotherapy for bone and soft tissue sarcomas. 
T. Kamada, R. Imai, H. Tsujii, H. Tsuji, I. Serizawa; National Institute of Radiological  Sciences, Chiba, Japan
Background: Carbon ion radiotherapy showed promising clinical outcomes in 57 patients with bone and STS during the phase I study (Kamada, JCO 22 4466-4471, 2002). This phase II study was planned thereafter.
Methods: From April 2000 to February 2007, 301 lesions of 282 patients with bone and STS not suited for surgical resection were enrolled in this phase II study. A total dose of 64.0 GyE in 16 fractions over 4 weeks was indicated for 15 lesions, that of 70.4 GyE for 276 and remaining 10 receiving 73.6 GyE. Mean age was 52 yrs, (range 12-85); site of origin was the pelvis in 74%, spine or para-spinous softtissue in 20%, extremities in 5%; bone primarywas in 78% and softtissue in 22%; pathologic subtype in bone sarcoma was chordoma in 42%, chondrosarcoma in 21%, osteosarcoma in 21%; pathologic subtype in STS was MFH in 23%, MPNST in 21%, synovial sarcoma in 13%. 
Results: The 3- and 5-year overall actuarial survival rates were 68% (95% Cl, 61%-75%) and 52% (95% Cl, 43%-61%), respectively, and the actuarial overall local control rates were 85% (95% Cl, 80%- 90%), and 81% (95% Cl, 74%-88%) at 3 years and 5 years of follow-up, respectively. Overall toxicity was acceptable, with 2% skin/soft tissue late G3/4 toxicity. 
Conclusions: Carbon ion radiotherapy shows a substantial local control in the patients with bone and soft tissue sarcomas not suited for surgical resection with acceptable morbidity.},
 pages = {562S--562S},
 title = {Carbon ion radiotherapy for bone and soft tissue sarcomas},
 volume = {26},
 year = {2008}
}